Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies
New license agreement expands Genprex’s oncology franchise Licensed technologies include use of Genprex’s TUSC2 gene therapy combined with immunotherapy drugs, including: Pembrolizumab (Merck’s largest selling drug Keytruda) Nivolumab (Bristol-Myers Squibb’s Opdivo) Ipilimumab (Bristol-Myers Squibb’s Yervoy) AUSTIN, Texas — (May 5, 2020) — Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage […]
Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes
Company licenses patented diabetes gene therapy technology designed by researchers at the University of Pittsburgh Results from in vivo animal studies indicate that normal glucose levels in the blood may be restored for an extended period of time Company plans to partner for the clinical development and commercialization of this therapy in the U.S. and […]
Genprex to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC)
Austin, TX & Cambridge, MA – Feburary 5, 2020- Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today provides a clinical update and focus for its Oncoprex™ immunogene therapy program for 2020, prioritizing the development of Oncoprex […]
